New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 8, 2012
10:20 EDTSNCR, RHHBY, EA, SYNC, NCMI, TNB, SIGA, MAKO, ERJ, ACM, EP, BPOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: AECOM Technology (ACM) downgraded to Underperform from Buy at BofA/Merrill... BP (BP) downgraded to Underweight from Equal Weight at Barclays... El Paso (EP) downgraded to Underweight from Neutral at Atlantic Equities... Embraer (ERJ) downgraded to Neutral from Buy at Citigroup... Mako Surgical (MAKO) downgraded to Neutral from Buy at Mizuho... National CineMedia (NCMI) downgraded to In-Line from Outperform at Imperial Capital... Roche (RHHBY) downgraded to Neutral from Overweight at JPMorgan... SIGA Technologies (SIGA) downgraded to Sector Perform from Outperform at RBC Capital... Synacor (SYNC) downgraded to Underperform from Buy at BofA/Merrill... Synchronoss (SNCR) downgraded to Market Perform from Outperform at Wells Fargo... Thomas & Betts (TNB) downgraded to Neutral from Outperform at RW Baird... Electronic Arts (EA) downgraded to Market Perform from Outperform at William Blair.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 >>
October 5, 2015
08:00 EDTEAeSports should drive higher valuations for game makers, says Baird
Subscribe for More Information
06:01 EDTEAElectronic Arts should be bought on any game launch selloff, says Piper Jaffray
Piper Jaffray analyst Michael Olson recommends buying shares of Electronic Arts on any "sell the news" around the November 17 Star Wars Battlefront launch. His analysis shows a "brief, and minor," pullback in shares of major game publishers following the launch of big titles. This selloff historically creates a buying opportunity, however, with publisher shares up an average of 40% in the 12 months following launch, Olson tells investors in a research note. He reiterates an Overweight rating on Electronic Arts with an $86 price target.
October 4, 2015
14:39 EDTRHHBYPTC presents Phase 2 data on RG7800 for spinal muscular atrophy
Subscribe for More Information
October 2, 2015
06:28 EDTBPBP in talks over deal with Iran, the Times reports
Subscribe for More Information
October 1, 2015
09:35 EDTBPActive equity options trading on open
Subscribe for More Information
September 30, 2015
17:48 EDTRHHBYPacific Biosciences launches new sequencing platform
Subscribe for More Information
September 29, 2015
08:06 EDTACMAECOM receives selective catalytic reduction retrofit contract with APS
AECOM has been selected for the project with Arizona Public Service to engineer, procure and construct selective catalytic reduction retrofits and related balance of plant equipment at the Four Corners Station near Farmington, N.M. AECOM will install SCR technology for APS Four Corners units 4 and 5 at the coal-fired power plants. AECOM has a three-decade history that represents the cleaning of more than 25,000 megawatts of coal-plant emissions and is an established market leader in SCR systems design and installation for both grassroots and retrofit projects. The project's value was included in AECOM's ending backlog for the third quarter.
September 28, 2015
16:38 EDTSYNCTZ Holdings reports 8% passive stake in Synacor
Subscribe for More Information
10:43 EDTRHHBYRoche to hold an analyst briefing with a conference call hookup
Subscribe for More Information
10:00 EDTBPOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:03 EDTBPBP initiated with an Outperform at BMO Capital
07:52 EDTRHHBYIIR Holdings to hold a conference
Subscribe for More Information
06:20 EDTBPBP not concerned over hostile takeover due to Macondo disclaimer, Bloomberg says
BP, which is allegedly readying defenses for potential acquisition offers, isn't concerned about a hostile takeover because of a disclaimer in its Macondo spill settlement that could put $12.6B onto the price tag, Bloomberg reports. A potential buyer may have to accelerate the payment of as much as two-thirds of the $18.7B in penalties BP agreed to pay the U.S. and several states, the report says, citing company filings. An option that provides the government and certain states the power to demand faster payment in a takeover basically hands them a veto over any deal, the report says. Reference Link
05:15 EDTRHHBYGenentech announces Phase III study of ocrelizumab met primary endpoint
Subscribe for More Information
September 27, 2015
17:02 EDTRHHBYNewLink Genetics reports early Phase 1a data on GDC-0919
Subscribe for More Information
16:42 EDTRHHBYRoche present Phase 2 results on atezolizumab for urothelial cancer
Subscribe for More Information
16:40 EDTRHHBYRoche reports results from two Phase 2 studies on atezolizumab
Genentech, a member of the Roche Group, announced results from two Phase 2 studies that evaluated the investigational cancer immunotherapy atezolizumab -- or anti-PDL1; MPDL3280A -- in people with advanced non-small cell lung cancer. In the randomized Phase 2 study POPLAR, atezolizumab met its primary endpoint and showed a statistically significant survival benefit compared to chemotherapy in people with recurrent NSCLC whose tumors expressed medium and high levels of PD-L1, which corresponded with people living 7.7 months longer than people who received docetaxel chemotherapy. A separate, single-arm Phase 2 study, BIRCH, met its primary endpoint and showed that atezolizumab shrank tumors in up to 27% of people whose disease had progressed on prior medicines and also expressed the highest levels of PD-L1. Median survival had not yet been reached. In both studies of atezolizumab, adverse events were consistent with those observed in previous studies. "We plan to submit these results to global health authorities to bring this potential new option to people as soon as possible," said Chief Medical Officer Sandra Horning.
September 25, 2015
07:42 EDTRHHBYExelixis: CHMP adopts positive opinion for cobimetinib, vemurafenib combination
Subscribe for More Information
07:22 EDTRHHBYEuropean Society for Medical Oncology to hold a conference
Subscribe for More Information
06:23 EDTRHHBYRoche CEO: Will see growth regardless of setbacks, Reuters reports
Roche Holding's product lineup is so good that the company will see growth regardless of setbacks, Reuters reports, citing an interview with CEO Severn Schwan with Finanz und Wirtschaft. "Roche could have six new active pharmaceutical ingredients approved within two years. We never had this before," Schwan said. Reference Link
1 | 2 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use